These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 36043503)

  • 1. A patent review of MAT2a inhibitors (2018-2021).
    Atkinson SJ; Evans L; Scott JS
    Expert Opin Ther Pat; 2022 Oct; 32(10):1043-1053. PubMed ID: 36043503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined inhibition of MTAP and MAT2a mimics synthetic lethality in tumor models via PRMT5 inhibition.
    Bedard GT; Gilaj N; Peregrina K; Brew I; Tosti E; Shaffer K; Tyler PC; Edelmann W; Augenlicht LH; Schramm VL
    J Biol Chem; 2024 Jan; 300(1):105492. PubMed ID: 38000655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pleiotropic effects of methionine adenosyltransferases deregulation as determinants of liver cancer progression and prognosis.
    Frau M; Feo F; Pascale RM
    J Hepatol; 2013 Oct; 59(4):830-41. PubMed ID: 23665184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MTAP Deletions in Cancer Create Vulnerability to Targeting of the MAT2A/PRMT5/RIOK1 Axis.
    Marjon K; Cameron MJ; Quang P; Clasquin MF; Mandley E; Kunii K; McVay M; Choe S; Kernytsky A; Gross S; Konteatis Z; Murtie J; Blake ML; Travins J; Dorsch M; Biller SA; Marks KM
    Cell Rep; 2016 Apr; 15(3):574-587. PubMed ID: 27068473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MAT2A Inhibition Blocks the Growth of MTAP-Deleted Cancer Cells by Reducing PRMT5-Dependent mRNA Splicing and Inducing DNA Damage.
    Kalev P; Hyer ML; Gross S; Konteatis Z; Chen CC; Fletcher M; Lein M; Aguado-Fraile E; Frank V; Barnett A; Mandley E; Goldford J; Chen Y; Sellers K; Hayes S; Lizotte K; Quang P; Tuncay Y; Clasquin M; Peters R; Weier J; Simone E; Murtie J; Liu W; Nagaraja R; Dang L; Sui Z; Biller SA; Travins J; Marks KM; Marjon K
    Cancer Cell; 2021 Feb; 39(2):209-224.e11. PubMed ID: 33450196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overview of Methionine Adenosyltransferase 2A (MAT2A) as an Anticancer Target: Structure, Function, and Inhibitors.
    Li C; Gui G; Zhang L; Qin A; Zhou C; Zha X
    J Med Chem; 2022 Jul; 65(14):9531-9547. PubMed ID: 35796517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SCR-7952, a highly selective MAT2A inhibitor, demonstrates synergistic antitumor activities in combination with the
    Yu Z; Kuang Y; Xue L; Ma X; Li T; Yuan L; Li M; Xue G; Li Z; Tang F; Tang J; Shan J; Wang W; Tang R; Zhou F
    MedComm (2020); 2024 Oct; 5(10):e705. PubMed ID: 39309689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the methionine-methionine adenosyl transferase 2A- S -adenosyl methionine axis for cancer therapy.
    Guo J; Yang Y; Buettner R; Rosen ST
    Curr Opin Oncol; 2022 Sep; 34(5):546-551. PubMed ID: 35788128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanistic safety assessment via multi-omic characterisation of systemic pathway perturbations following in vivo MAT2A inhibition.
    Fogal V; Michopoulos F; Jarnuczak AF; Hamza GM; Harlfinger S; Davey P; Hulme H; Atkinson SJ; Gabrowski P; Cheung T; Grondine M; Hoover C; Rose J; Bray C; Foster AJ; Askin S; Majumder MM; Fitzpatrick P; Miele E; Macdonald R; Keun HC; Coen M
    Arch Toxicol; 2024 Aug; 98(8):2589-2603. PubMed ID: 38755480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of AG-270, a First-in-Class Oral MAT2A Inhibitor for the Treatment of Tumors with Homozygous
    Konteatis Z; Travins J; Gross S; Marjon K; Barnett A; Mandley E; Nicolay B; Nagaraja R; Chen Y; Sun Y; Liu Z; Yu J; Ye Z; Jiang F; Wei W; Fang C; Gao Y; Kalev P; Hyer ML; DeLaBarre B; Jin L; Padyana AK; Dang L; Murtie J; Biller SA; Sui Z; Marks KM
    J Med Chem; 2021 Apr; 64(8):4430-4449. PubMed ID: 33829783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The potential and challenges of targeting
    Bray C; Balcells C; McNeish IA; Keun HC
    Front Oncol; 2023; 13():1264785. PubMed ID: 37795443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leveraging Structure-Based Drug Design to Identify Next-Generation MAT2A Inhibitors, Including Brain-Penetrant and Peripherally Efficacious Leads.
    Li M; Konteatis Z; Nagaraja N; Chen Y; Zhou S; Ma G; Gross S; Marjon K; Hyer ML; Mandley E; Lein M; Padyana AK; Jin L; Tong S; Peters R; Murtie J; Travins J; Medeiros M; Liu P; Frank V; Judd ET; Biller SA; Marks KM; Sui Z; Reznik SK
    J Med Chem; 2022 Mar; 65(6):4600-4615. PubMed ID: 35293760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Homozygous MTAP deletion in primary human glioblastoma is not associated with elevation of methylthioadenosine.
    Barekatain Y; Ackroyd JJ; Yan VC; Khadka S; Wang L; Chen KC; Poral AH; Tran T; Georgiou DK; Arthur K; Lin YH; Satani N; Ballato ES; Behr EI; deCarvalho AC; Verhaak RGW; de Groot J; Huse JT; Asara JM; Kalluri R; Muller FL
    Nat Commun; 2021 Jul; 12(1):4228. PubMed ID: 34244484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of novel MAT2A inhibitors by an allosteric site-compatible fragment growing approach.
    Gao F; Ding X; Cao Z; Zhu W; Fan Y; Steurer B; Wang H; Cai X; Zhang M; Aliper A; Ren F; Ding X; Zhavoronkov A
    Bioorg Med Chem; 2024 Feb; 100():117633. PubMed ID: 38342078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The combination of methionine adenosyltransferase 2A inhibitor and methyltransferase like 3 inhibitor promotes apoptosis of non-small cell lung cancer cells and produces synergistic anti-tumor activity.
    Xuan YF; Lu S; Ou YJ; Bao XB; Huan XJ; Song SS; Miao ZH; Wang YQ
    Biochem Biophys Res Commun; 2024 Jul; 716():150011. PubMed ID: 38704890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and Structural Optimization of Methionine Adenosyltransferase 2A (MAT2A) Inhibitors with High In Vivo Potency and Oral Bioavailability.
    Zhang S; Qing L; Wang Z; Zhang Y; Li Y; Fang H; Liu Y; He H
    J Med Chem; 2023 Apr; 66(7):4849-4867. PubMed ID: 36961373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5.
    Mavrakis KJ; McDonald ER; Schlabach MR; Billy E; Hoffman GR; deWeck A; Ruddy DA; Venkatesan K; Yu J; McAllister G; Stump M; deBeaumont R; Ho S; Yue Y; Liu Y; Yan-Neale Y; Yang G; Lin F; Yin H; Gao H; Kipp DR; Zhao S; McNamara JT; Sprague ER; Zheng B; Lin Y; Cho YS; Gu J; Crawford K; Ciccone D; Vitari AC; Lai A; Capka V; Hurov K; Porter JA; Tallarico J; Mickanin C; Lees E; Pagliarini R; Keen N; Schmelzle T; Hofmann F; Stegmeier F; Sellers WR
    Science; 2016 Mar; 351(6278):1208-13. PubMed ID: 26912361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting S-adenosylmethionine biosynthesis with a novel allosteric inhibitor of Mat2A.
    Quinlan CL; Kaiser SE; Bolaños B; Nowlin D; Grantner R; Karlicek-Bryant S; Feng JL; Jenkinson S; Freeman-Cook K; Dann SG; Wang X; Wells PA; Fantin VR; Stewart AE; Grant SK
    Nat Chem Biol; 2017 Jul; 13(7):785-792. PubMed ID: 28553945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fragment-Based Design of a Potent MAT2a Inhibitor and
    De Fusco C; Schimpl M; Börjesson U; Cheung T; Collie I; Evans L; Narasimhan P; Stubbs C; Vazquez-Chantada M; Wagner DJ; Grondine M; Sanders MG; Tentarelli S; Underwood E; Argyrou A; Smith JM; Lynch JT; Chiarparin E; Robb G; Bagal SK; Scott JS
    J Med Chem; 2021 May; 64(10):6814-6826. PubMed ID: 33900758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transition state analogue of MTAP extends lifespan of APC
    Firestone RS; Feng M; Basu I; Peregrina K; Augenlicht LH; Schramm VL
    Sci Rep; 2021 Apr; 11(1):8844. PubMed ID: 33893330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.